A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Nasim Kiaie, Armita Mahdavi Gorabi, Peter E. Penson, Gerald Watts, Thomas P. Johnston, Maciej Banach, Amirhossein Sahebkar

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.

Original languageEnglish
Pages (from-to)58-72
Number of pages15
JournalDrug Discovery Today
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 2020

Fingerprint Dive into the research topics of 'A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome'. Together they form a unique fingerprint.

Cite this